cytogenetic knowledge. Standard of practice-that is, in-house protocols-should be established for the processing of tissue and cell types, culture setup, analysis, quality control, and turnaround times based on the reason for the cytogenetic testing (for example, initial diagnosis or follow-up) and the clinical utility of the cytogenetic information (for example, diagnosis, prognostic value, or selection of therapy). All cytogenetic findings should be interpreted in the context of clinical, morphologic, and other laboratory findings whenever possible. Molecular assays are also available for many of the neoplastic disorders described in the guidelines, and the implementation and use of specific molecular tests is based on the funding and capability of the local genetic centre. In addition, clinical microarray platforms for oncology are currently being developed and evaluated by the Cancer Cytogenomics Microarray Consortium (http://www. urmc.rochester.edu/ccmc/) clinical trial group.
GUIDELINES

Indications for Cancer Cytogenetic Investigations
A complete cytogenetic analysis of bone marrow should be performed
• at the time of initial evaluation to establish the cytogenetic profile, and • at intervals thereafter as clinically indicated to detect persistence of an abnormal clone or evidence of genetic or clonal evolution.
A standard of practice for the cancer cytogenetics of specific neoplastic disorders, including fluorescence in situ hybridization (fish), should be established at each genetic centre. The neoplastic disorders listed in the rest of this subsection accord with the 2008 World Health Organization classification of tumours of hematopoietic and lymphoid tissues and of tumours of soft tissue and bone 1 . The
ABSTRACT
The Canadian College of Medical Geneticists (ccmg) is a national organization of medical and laboratory geneticists. The mission of the ccmg is to establish and maintain high-quality professional and ethical standards for medical genetics services in Canada and to help to ensure that service of the highest quality is delivered to the Canadian public.
Cancer cytogenetics is one of the sections of practice of the ccmg. The ccmg Cytogenetic Committee has, therefore, put forward guidelines to provide oncologists and ccmg cytogeneticists with a comprehensive review of the cytogenetic diagnostic tests that are recommended as a minimum standard of care for tumours of hematopoietic and lymphoid tissues and for tumours of soft tissue and bone. The guidelines were approved by the ccmg board of directors in June 2010.
INTRODUCTION
The Canadian College of Medical Geneticists (ccmg) guidelines are compiled from various sources and are based primarily on expert opinion and descriptive papers that demonstrate the value of cytogenetics in the diagnosis, prognosis, and management of neoplasia. The indications for cancer cytogenetics are not all-inclusive and may be extended where there is local interest. The guidelines that follow are minimum recommendations only. They are subject to the discretion of the laboratory director and to the requirements, capabilities, and funding of the local cytogenetic laboratory. The guidelines are based on the information that was available at the time of writing, and they will change with advances in 
Myelodysplastic Syndromes
Karyotype at diagnosis, especially in the patient eligible for a bone marrow transplant. Follow-up investigation may be indicated at disease progression and after treatment.
Acute Leukemia, Myeloid and Lymphoid
Karyotype all cases, with fish as indicated based on chromosome morphology and clinical and pathologic features. If an abnormality is present, a follow-up after treatment or at relapse may be indicated. If an abnormal clone is not detected, re-investigation at relapse may be indicated in a second attempt to detect a disease-related clone.
Mature B-Cell Neoplasms Chronic Lymphocytic Leukemia:
Fluorescence in situ hybridization to detect abnormalities such as +12, del(13)(q14), or deletion of ATM and TP53 can be performed. The specific fish loci to be tested and the need for conventional karyotyping would depend on the policy of the local centre.
Plasma Cell Myeloma: At a minimum, fish to detect abnormalities such as t(4:14)(p16;q32) and deletion of TP53 should be performed. The specific fish loci to be tested and the need for conventional karyotyping will depend on the policy of the local centre. Investigations should preferentially target the analysis of plasma cells.
Karyotype or fish, or both, may be appropriate at diagnosis in selected cases, in consultation with the pathologist or clinician, for these disorders:
• Marginal zone lymphoma or mucosa-associated lymphoid tissue lymphoma • Follicular lymphoma • Mantle cell lymphoma • Diffuse large B-cell lymphoma • Burkitt lymphoma
T-Cell Neoplasms
• T-Cell prolymphocytic leukemia • Hepatosplenic T-cell lymphoma • Anaplastic large cell lymphoma
Solid Tumours
Karyotype or fish, or both, may be appropriate at diagnosis for small-round-cell tumours of childhood, selected sarcomas, lipomatous tumours, and other tumours, in consultation with the pathologist or clinician. In consultation with the pathologist or clinician, fish may also be used for the diagnosis and prognosis of some carcinomas-for example, bladder, prostate, breast. Exception: In cases of confirmed pediatric pre-B-cell acute lymphoblastic leukemia (all), identification of the abnormal clone by more extensive analysis is warranted.
Recommendations for the Processing of Cancer Cytogenetic Specimens
Post-Treatment Monitoring:
Examine sufficient metaphases (minimum of 10) to confirm the presence of the original abnormal clone. If normal, examine at least 25 metaphases.
Karyotype at least 1 metaphase per stem line and significant side line. A normal metaphase (when present) should be printed; a normal karyotype is recommended. Karyotype at least 1 metaphase per stem line and significant side line. A normal metaphase (when present) should be printed; a normal karyotype is recommended.
Mature B-Cell
Recommendations for FISH Analysis of Cancer Specimens
General
• In some situations, fish is helpful in patient management because, compared with chromosome analysis, it provides greater sensitivity or a more rapid result, or both. The extent of analysis will depend on local resources and the availability of molecular diagnostics. 
Sex Chromosomes
After bone marrow transplantation involving an opposite-sex donor, use dual-color probes to examine a minimum of 200 interphase nuclei or 50 metaphase cells for the X and Y chromosome 6,7 .
Numerical Abnormalities
• At diagnosis, fish with centromeric probes can be used to examine poor-quality metaphases or interphase nuclei for numerical chromosome abnormalities. This approach is particularly useful when the abnormality being sought has prognostic value-for example, -7 in myelodysplastic syndrome or acute myelogenous leukemia, and +4/+10/+17 in all.
• At follow-up of a patient with a known numerical abnormality, interphase fish can be used to detect residual disease.
• Gene amplification can be detected by fish analysis as multiple fluorescence signals (more than the normal diploid copy number)-for example, her2/neu (ERBB2) in breast carcinoma or NMYC in neuroblastoma. or BCR/ABL1 rearrangements in chronic myeloproliferative neoplasms.
Translocation and Deletion Detection
• Fluorescence in situ hybridization can be used to clarify ambiguous or complex rearrangements, or to assist in clarifying rearrangements when morphology is poor (for example, to confirm the involvement of mixed lineage leukemia in an 11q23 rearrangement) • Interphase fish can be useful at follow-up to detect specific structural abnormalities such as t(9;22) 8 . Analyze a minimum of 200 nuclei.
Marker Identification
In individual cases, identification of a marker chromosome may be clinically significant. Paint probes or multicolor fish techniques can be used in an attempt to identify markers.
Recommendation for Turnaround Time to Completion of Reports
Local policies have to be established, and guidelines for those policies are suggested below. Final written reports for at least 90% of all neoplastic analyses should be completed within the recommended turnaround times listed below.
• For cytogenetics and fish, and depending on the clinical indication (for example, acute promyelocytic leukemia for treatment purposes), a preliminary result should be reported within 3-5 days, with the final written report being completed within 2 weeks. • For routine cytogenetics or fish, or both, at diagnosis for all, acute myelogenous leukemia, and chronic myelogenous leukemia, final results should be reported within 2 weeks. Results for other neoplastic disorders may be reported within 3 weeks. • For routine cytogenetics or fish, or both, at follow-up, final results should be reported within 3 weeks. 
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